NCT01911507View on ClinicalTrials.gov

INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

August 27, 2013

Primary Completion Date

August 26, 2020

Study Completion Date

August 26, 2020

Conditions

Recurrent Non-small Cell Lung Cancer

Interventions

DRUG

INC280

Given PO

DRUG

erlotinib hydrochloride

Given PO

Trial Locations (2)

94115

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

95817

University of California, Davis, Sacramento

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

University of California, Davis

OTHER